Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Jagsonpal Pharmaceuticals
Start SIPJagsonpal Pharmaceuticals Investment Rating
-
Master Rating:
-
Jagsonpal Pharmaceuticals has an operating revenue of Rs. 227.73 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 107 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 61 | 61 | 52 |
| Operating Expenses Qtr Cr | 48 | 54 | 52 |
| Operating Profit Qtr Cr | 13 | 6 | 1 |
| Depreciation Qtr Cr | 0 | 0 | 1 |
| Interest Qtr Cr | 0 | 0 | 0 |
| Tax Qtr Cr | 3 | 0 | 0 |
| Net Profit Qtr Cr | 10 | 0 | 0 |
Jagsonpal Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 1
- Bearish Moving Average
- ___
- 15
- 20 Day
- 355.21
- 50 Day
- 357.58
- 100 Day
- 353.14
- 200 Day
- 329.7
- 20 Day
- 359.88
- 50 Day
- 359.23
- 100 Day
- 356.07
- 200 Day
- 342.56
Jagsonpal Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 346.54 |
| Second Resistance | 357.92 |
| Third Resistance | 365.19 |
| RSI | 30.37 |
| MFI | 20.36 |
| MACD Single Line | -2.54 |
| MACD | -6.44 |
| Support | |
|---|---|
| First Resistance | 327.89 |
| Second Resistance | 320.62 |
| Third Resistance | 309.24 |
Jagsonpal Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 24,528 | 1,380,681 | 56.29 |
| Week | 13,948 | 815,272 | 58.45 |
| 1 Month | 20,724 | 956,406 | 46.15 |
| 6 Month | 48,359 | 2,265,623 | 46.85 |
Jagsonpal Pharmaceuticals Result Highlights
Jagsonpal Pharmaceuticals Synopsis
NSE-Medical-Diversified
Jagsonpal Pharma belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 226.10 Cr. and Equity Capital is Rs. 13.10 Cr. for the Year ended 31/03/2022. Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181.| Market Cap | 867 |
| Sales | 228 |
| Shares in Float | 0.81 |
| No of funds | 6 |
| Yield | 1.07 |
| Book Value | 7.04 |
| U/D Vol ratio | 1.8 |
| LTDebt / Equity | |
| Alpha | 0.33 |
| Beta | 0.86 |
Jagsonpal Pharmaceuticals
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 68.71% | 68.71% | 68.71% | |
| Mutual Funds | ||||
| Foreign Portfolio Investors | 0.11% | 0.13% | ||
| Financial Institutions/ Banks | ||||
| Individual Investors | 21.12% | 22.77% | 25.26% | |
| Others | 10.06% | 8.39% | 6.03% |
Jagsonpal Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. R P S Kochhar | Chairman Emeritus |
| Mr. Manish Gupta | Managing Director |
| Mr. Harsha Raghavan | Non Executive Director |
| Mr. Prithipal Singh Kochhar | Non Executive Director |
| Mr. Debasis Bikash Nandy | Ind. Non-Executive Director |
| Ms. Radhika Madhukar Dudhat | Ind. Non-Executive Director |
| Ms. Pallavi Dinodia Gupta | Ind. Non-Executive Director |
Jagsonpal Pharmaceuticals Forecast
Price Estimates
Jagsonpal Pharmaceuticals Corporate Action
Jagsonpal Pharmaceuticals FAQs
What is Share Price of Jagsonpal Pharmaceuticals ?
Jagsonpal Pharmaceuticals share price is ₹332 As on 05 February, 2023 | 17:09
What is the Market Cap of Jagsonpal Pharmaceuticals ?
The Market Cap of Jagsonpal Pharmaceuticals is ₹872 Cr As on 05 February, 2023 | 17:09
What is the P/E ratio of Jagsonpal Pharmaceuticals ?
The P/E ratio of Jagsonpal Pharmaceuticals is 53.8 As on 05 February, 2023 | 17:09
What is the PB ratio of Jagsonpal Pharmaceuticals ?
The PB ratio of Jagsonpal Pharmaceuticals is 7.1 As on 05 February, 2023 | 17:09